Edgar Filing: Kennedy Joseph T - Form 4

Kennedy Josep Form 4	oh T									
December 20,	2011									
FORM	4								PPROVAL	
	UNITED	STATES		RITIES A shington			E COMMISSIO	N OMB Number:	3235-0287	
Check this l if no longer subject to Section 16. Form 4 or Form 5 obligations	Section	NGES IN SECUI 16(a) of th	Estimated burden hou response	Estimated average burden hours per response 0.5						
may continu <i>See</i> Instruct 1(b).	ue.			•	•	npany Act ny Act of 1	of 1935 or Secti 1940	on		
(Print or Type Res	sponses)									
1. Name and Add Kennedy Jose	Symbol	er Name an RIN CORI		Trading K [AMRN	5. Relationship of Reporting Person(s) to Issuer(Check all applicable)					
(Last)	(First) (I	Middle)	3. Date of	of Earliest T	ransaction		(Chi	ek an applicabl	5)	
C/O AMARIN PHARMA, INC., 1430 ROUTE 206, SUITE 200			(Month/Day/Year) 12/16/2011				Director 10% Owner X Officer (give title Other (specify below) below) Senior VP and General Counsel			
BEDMINSTE	4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
							Person			
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	Transaction Date Ionth/Day/Year)	2A. Deema Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report	t on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					Perso inform requir	ns who re nation con red to resp iys a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Kennedy Joseph T - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 6.35	12/16/2011		A		600,000		(1)	12/16/2021	Ordinary Shares (2)	600,000

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Kennedy Joseph T C/O AMARIN PHARMA, INC. 1430 ROUTE 206, SUITE 200 BEDMINSTER, NJ 07921			Senior VP and General Counsel					
Signatures								
/s/ Frederick Ahlholm, by power attorney	of	12/20)/2011					

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Option vests and becomes exercisable as follows: 25% of the total number of underlying shares shall vest on December 16, 2012 and the remaining 75% of the underlying shares shall vest ratably over the subsequent 36 months.

(2) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.